|

IDP-023 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Indapta Therapeutics, INC.1

Indications

  • NHL1
  • Relapsed Multiple Myeloma1
  • Refractory Multiple Myeloma1
  • Blood Cancer1
  • Refractory Non-Hodgkin Lymphoma1

Los Angeles, California1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.